A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2015
At a glance
- Drugs Tipifarnib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 09 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 May 2013 Planned end date changed from 1 Dec 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 22 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.